Principle investigator of YELLOW III, Dr Annapoorna Subhash Kini (Mount Sinai Hospital, US) joins us to talk about the study that assessed the effect of evolocumab (Repatha) on coronary plaque morphology using intravascular imaging and gene expression analysis of peripheral blood mononuclear cells (PBMC) in 140 patients with stable CAD on maximally tolerated statin therapy.
The study showed that more intensive lipid lowering
with addition of evolocumab for 26 weeks resulted in significant and substantial increase
in the minimum FCT by OCT, reduction in NIRS maxLCBI4mm and reduction in atheroma
volume by IVUS in angiographically non-obstructive lesions.
Questions:
1. What prompted the YELLOW studies?
2. What are the baseline characteristics of the enrolled patients?
3. What are the key findings presented at ACC?
4. What are the potential implications for patient care?
For more content from ACC.23/WCC head to the Late-Breaking Science Video Collection.
Recorded on-site at ACC.23, New Orleans.
Visit Radcliffe Cardiology: [ Ссылка ]
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook: [ Ссылка ]
Follow us on Twitter: [ Ссылка ]
